Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;22(5):499-503.
doi: 10.1097/BOR.0b013e32833c62b0.

Interleukin-17-producing T cells in lupus

Affiliations
Review

Interleukin-17-producing T cells in lupus

José C Crispín et al. Curr Opin Rheumatol. 2010 Sep.

Abstract

Purpose of review: Interleukin-17 (IL-17) has emerged as a key cytokine involved in the pathogenesis of autoimmune diseases. In this article, we review recently produced evidence obtained in patients and murine models of lupus that link increased IL-17 production with lupus pathology and discuss the potential roles IL-17 may play in the pathogenesis of systemic lupus erythematosus.

Recent findings: IL-17 may promote autoantibody production and IL-17-producing cells are found in afflicted organs in humans and lupus-prone mice. TH17 and CD3+CD4-CD8- cells are expanded in systemic lupus erythematosus patients and account for the increased production of IL-17. Genetic silencing of genes involved in the increased production of IL-17 in lupus-prone mice as well as treatment of mice with lupus using biologic agents that result in decreased IL-17 production leads invariably to disease mitigation.

Summary: The presented evidence strongly argues for the introduction of IL-17-suppressing biologics in the treatment of patients with systemic lupus erythematosus.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms